论文部分内容阅读
目的:探讨环孢素A(C sA)联合沙利度胺、造血生长因子低增生骨髓增生异常综合征(hypo-M DS)的临床疗效。方法:采用环孢素A联合沙利度胺、造血生长因子治疗低增生性骨髓异常综合征(hypo-M DS)患者20例,定期观察患者外周血象和骨髓细胞形态学,并随诊观察远期疗效。结果:17例患者治疗总有效率为80.0%(16/20),75.0%(15/20)患者血液学指标改善并摆脱输血依赖,全部患者无严重毒副反应出现。结论:C sA联合沙利度胺、造血生长因子治疗低危骨髓增生异常综合征疗效可靠,耐受性好。
Objective: To investigate the clinical efficacy of cyclosporine A (C sA) in combination with thalidomide and hematopoietic growth factor hypo-myelodysplastic syndrome (hypo-M DS). Methods: Twenty patients with hypo-proliferative myelodysplastic syndrome (hypo-M DS) were treated with cyclosporin A combined with thalidomide and hematopoietic growth factor. Peripheral blood and bone marrow cell morphology were observed regularly. The patients were followed up far Period of efficacy. Results: The total effective rate of the 17 patients was 80.0% (16/20). The hematological indexes of 75.0% (15/20) patients were improved and got rid of the blood transfusion dependent. All the patients had no serious side effects. Conclusion: C sA combined with thalidomide and hematopoietic growth factor are effective and tolerable in the treatment of low risk myelodysplastic syndromes.